Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A
US8802620B2 · kind B2 · utility
3Cited by
1References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 21, 2008 |
| Grant date | Aug 12, 2014 |
| Priority date | — |
| Expiry date | Oct 7, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.